42 related articles for article (PubMed ID: 28508388)
1. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
Ahmed AR; Aksoy M
Front Immunol; 2021; 12():727520. PubMed ID: 34646266
[TBL] [Abstract][Full Text] [Related]
2. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin.
Sami N; Bhol KC; Ahmed AR
Clin Exp Immunol; 2002 Sep; 129(3):533-40. PubMed ID: 12197896
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid.
Le ST; Herbert S; Haughton R; Nava J; Toussi A; Ji-Xu A; Maverakis E
JAMA Dermatol; 2024 Jan; 160(1):107-109. PubMed ID: 37991748
[TBL] [Abstract][Full Text] [Related]
4. [Bullous Pemphigoid Successfully Treated with Rituximab].
Silva N; Costa A; Salvador F; Serradeiro E
Acta Med Port; 2017 Mar; 30(3):243-246. PubMed ID: 28550834
[TBL] [Abstract][Full Text] [Related]
5. Infantile bullous pemphigoid successfully treated with intravenous immunoglobulin therapy.
Watanabe T; Hara S; Muto J; Watanabe D; Akiyama M
Clin Exp Dermatol; 2017 Jul; 42(5):576-578. PubMed ID: 28543802
[No Abstract] [Full Text] [Related]
6. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.
Amber KT; Maglie R; Solimani F; Eming R; Hertl M
Drugs; 2018 Oct; 78(15):1527-1548. PubMed ID: 30238396
[TBL] [Abstract][Full Text] [Related]
8. BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.
Liu Y; Li L; Xia Y
Front Immunol; 2017; 8():1752. PubMed ID: 29276517
[TBL] [Abstract][Full Text] [Related]
9. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
Nigam R; Levitt J
J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
[TBL] [Abstract][Full Text] [Related]
10. Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin.
Nguyen T; Ahmed AR
Clin Exp Dermatol; 2017 Jul; 42(5):516-519. PubMed ID: 28508388
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
[TBL] [Abstract][Full Text] [Related]
12. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
13. Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.
Tekin B; Yücelten AD
Pediatr Dermatol; 2015; 32(5):723-6. PubMed ID: 26119800
[TBL] [Abstract][Full Text] [Related]
14. "Half-half" blisters in bullous pemphigoid successfully treated with adjuvant high-dose intravenous immunoglobulin.
Pacheco D; Lopes L; Soares-Almeida L; Marques MS; Filipe P
Acta Dermatovenerol Alp Pannonica Adriat; 2012 Sep; 21(3):59-61. PubMed ID: 23267874
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
